2. Search Result
Search Result
Results for "

LDHA+inhibitor

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100681
    GSK2837808A
    Maximum Cited Publications
    43 Publications Verification

    		 Lactate Dehydrogenase Cancer
    GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.
    GSK2837808A
  • HY-16214
    FX-11
    25+ Cited Publications

    LDHA Inhibitor FX11

    		 Lactate Dehydrogenase Apoptosis Reactive Oxygen Species (ROS) Cancer
    FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a Ki of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts .
    FX-11
  • HY-100742A
    (R)-GNE-140
    15+ Cited Publications

    		 Lactate Dehydrogenase Cancer
    (R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor, with IC50s of 3 nM and 5 nM for LDHA and LDHB, respectively; (R)-GNE-140 is 18-fold more potent than S enantiomer.
    (R)-GNE-140
  • HY-100742
    GNE-140 racemate
    5+ Cited Publications

    		 Lactate Dehydrogenase Cancer
    GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. GNE-140 racemate is a potent lactate dehydrogenase A (LDHA) inhibitor .
    GNE-140 racemate
  • HY-18968
    AZ-33
    1 Publications Verification

    LDHA-IN-4

    		 Lactate Dehydrogenase Cancer
    AZ-33 (LDHA-IN-4) (compound 33) is a selective lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 0.5 μM and a Kd of 0.093 μM .
    AZ-33
  • HY-124309
    NHI-2

    		Lactate Dehydrogenase Apoptosis Cancer
    NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 14.7 µM. NHI-2 shows selective for LDHA over LDHB (IC50 = 55.8 µM). NHI-2 is an efficient anti-glycolytic agent. NHI-2 enhances apoptosis, induces cell cycle arrest at S and G2 phases. NHI-2 has a broad spectrum anti-proliferative activity in cancer cells. NHI-2 affects extracellular acidification rate and ATP production. NHI-2 suppresses tumor growth in murine B78 melanoma tumor model .
    NHI-2
  • HY-139319
    LDHA-IN-3
    2 Publications Verification

    		 Lactate Dehydrogenase Cancer
    LDHA-IN-3 (compound 2), as a selenobenzene compound, is a potent, noncompetitive lactate dehydrogenase (LDHA) inhibitor (IC50=145.2 nM). LDHA-IN-3 can be used for the research of cancer .
    LDHA-IN-3
  • HY-156683
    CHK-336

    		Lactate Dehydrogenase Metabolic Disease
    CHK-336 (Example 1) is an orally active LDHA inhibitor (IC50<1 nM). CHK-336 inhibits lactate production in mouse hepatocytes. CHK-336 can be used in the study of hyperoxaluria .
    CHK-336
  • HY-175230
    ZG-2492

    		Lactate Dehydrogenase Apoptosis Cancer
    ZG-2492 is an orally active LDHA inhibitor with an IC50 of 156 nM. ZG-2492 can reduce lactate production and induce cell cycle arrest and apoptosis in pancreatic cancer cells . ZG-2492 has antitumor activity and can be used in the research of tumors such as pancreatic cancer .
    ZG-2492
  • HY-115875
    LDHA-IN-5

    		Lactate Dehydrogenase Metabolic Disease
    LDHA-IN-5 is a novel, potent, dual GO/LDHA inhibitor for primary hyperoxaluria.
    LDHA-IN-5
  • HY-178461
    LDHA-IN-10

    		Lactate Dehydrogenase Cancer
    LDHA-IN-10 (Compound HP19) is a Lactate Dehydrogenase-A (LDHA) inhibitor with an IC50 value of 5.2 μM. LDHA-IN-10 reduces lactate production and ATP levels, inhibiting the proliferation of pancreatic cancer cell line PANC-1. LDHA-IN-10 induces G1/S cell cycle arrest and promotes apoptosis. LDHA-IN-10 is promising for research of pancreatic ductal adenocarcinoma (PDAC) .
    LDHA-IN-10
  • HY-169060
    LDHA-IN-8

    		Lactate Dehydrogenase Cancer
    LDHA-IN-8 (Compound 6) is a lactate dehydrogenase (LDHA) inhibitor. LDHA-IN-8 inhibits LDHA catalysis of pyruvate in a dose-dependent manner (EC50 value of 14.54 μM), reduces intracellular lactate levels, and increases intracellular reactive oxygen species (ROS) levels, thereby inhibiting the proliferation of pancreatic cancer cells and lung cancer cells. LDHA-IN-8 holds promise for research in the field of LDHA-related antitumor therapies .
    LDHA-IN-8
  • HY-100681R
    GSK2837808A (Standard)

    		Lactate Dehydrogenase Reference Standards Cancer
    GSK2837808A (Standard) is the analytical standard of GSK2837808A (HY-100681). This product is intended for research and analytical applications. GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.
    GSK2837808A (Standard)
  • HY-100742R
    GNE-140 racemate (Standard)

    		Lactate Dehydrogenase Reference Standards Cancer
    GNE-140 (racemate) (Standard) is the analytical standard of GNE-140 (racemate) (HY-100742). This product is intended for research and analytical applications. GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. GNE-140 racemate is a potent lactate dehydrogenase A (LDHA) inhibitor .
    GNE-140 racemate (Standard)
  • HY-100742AR
    (R)-GNE-140 (Standard)

    		Lactate Dehydrogenase Reference Standards Cancer
    (R)-GNE-140 (Standard) is the analytical standard of (R)-GNE-140 (HY-100742A). This product is intended for research and analytical applications. (R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor, with IC50s of 3 nM and 5 nM for LDHA and LDHB, respectively; (R)-GNE-140 is 18-fold more potent than S enantiomer.
    (R)-GNE-140 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: